Shield Therapeutics - Investor Presentation
Released
RNS Number : 2378J
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Investor Presentation
London, UK, 21 December 2020:Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that a recording of the online Company presentation, which was delivered live by Tim Watts, Chief Executive Officer on Wednesday 16 December 2020 is now available to watch back on the Company's website here: Investors Videos and Audio | Shield Therapeutics and on the Investor Meet Company platform at https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor. The Q&A has also been published following the meeting.
For further information please contact:
Shield Therapeutics plc | |
Tim Watts, CEO | +44 (0)20 7186 8500 |
Nominated Adviser and Joint Broker | |
Peel Hunt LLP | |
James Steel/Dr Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane |
+44 (0)20 7220 0500 |
Financial PR & IR Advisor |
|
Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne | +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the
London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
use the personal data you provide us, please see our Privacy Policy.
END
NRATPBRTMTTBBLM
Share your feedback
Discover